
Sign up to save your podcasts
Or


Dalbavancin, a long-acting IV lipoglycopeptide, may be an option for the treatment of complicated Staphylococcus aureus bacteremia without requiring long-term IV access. Author Thomas L. Holland, MD, MSc, from Duke University School of Medicine discusses key points of the DOTS randomized clinical trial and more with JAMA Deputy Editor Preeti Malani, MD, MSJ. Related Content:
By JAMA Network4.6
162162 ratings
Dalbavancin, a long-acting IV lipoglycopeptide, may be an option for the treatment of complicated Staphylococcus aureus bacteremia without requiring long-term IV access. Author Thomas L. Holland, MD, MSc, from Duke University School of Medicine discusses key points of the DOTS randomized clinical trial and more with JAMA Deputy Editor Preeti Malani, MD, MSJ. Related Content:

6,699 Listeners

43,540 Listeners

38,764 Listeners

21,636 Listeners

138 Listeners

322 Listeners

702 Listeners

498 Listeners

764 Listeners

881 Listeners

3,337 Listeners

21 Listeners

13 Listeners

16 Listeners

7 Listeners

18 Listeners

30 Listeners

194 Listeners

88 Listeners

367 Listeners

6,362 Listeners

19 Listeners